Novavax
Mark Casey is the Chief Legal Officer and Corporate Secretary at Novavax, having previously held the same titles at Bryn Pharma. With extensive experience in the pharmaceutical and healthcare industries, Mark served as Executive Chairman of the Board for Mallinckrodt Pharmaceuticals' Specialty Generics Division, leading strategic turnaround efforts to enhance profitability. As Executive Vice President and Chief Legal Officer at Mallinckrodt, Mark directed the transformation of a $2+ billion company and managed various legal functions. Mark's earlier roles include General Counsel at Idera Pharmaceuticals, where responsibilities included building the legal and compliance functions, and multiple senior legal positions at Hologic, enhancing operations through significant mergers and acquisitions. Mark's career began at Boston Scientific Corp and EMC Corp, contributing expertise in intellectual property and patent management. Mark holds a Doctor of Law from Suffolk University Law School and a Bachelor of Science in Electrical Engineering from Syracuse University.
This person is not in any offices
Novavax
11 followers
Novavax is a late-stage biotechnology company dedicated to improving health globally through the discovery, development, and commercialization of innovative vaccines.